Protective Antibody Level After COVID-19 Vaccination Among Patients Under Hemodialysis

Evaluation of Protective Antibody Production After COVID-19 Vaccination Among Patients Under Hemodialysis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04871945

Enrollment

Registered

2021-05-04

Start date

2021-04-20

Completion date

2021-10-31

Last updated

2022-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19, End-stage Renal Disease, Hemolysis, Vaccine Reaction

Brief summary

The aim of the study is to evaluate the level of neutralizing antibody against SARS-CoV-2 after COVID-19 vaccination in patients under hemodialysis. To this end, the level of neutralizing antibody of patients under hemodialysis is compared to that of healthy population.

Interventions

DIAGNOSTIC_TESTElecsys Anti-SARS-CoV-2 S (Roche Diagnostics GmbH, Mannheim, Germany), 2) ACCESS SARS-CoV-2 IgG II (Beckman Coulter, Inc. USA)

The antibody level will be measured by the above mentioned methods. The trial drugs are not used but the vaccine that included in National Immunization Program for COVID-19 in Korea will be used for the study.

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* The person who is vaccinated with ChAdOx1 (COVID-19 vaccine) * The person who agrees with the protocol of the study

Exclusion criteria

* Age \< 18 years * Pregnants * Experience of COVID-19 infection

Design outcomes

Primary

Measure	Time frame
The change in the level of neutralizing antibody against SARS-CoV-2	Day 0, 14, 28, 56, 91, 120

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026